CC
TSHA icon

Casdin Capital’s Taysha Gene Therapies TSHA Stock Holding History

Casdin Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.1M Hold
3,250,000
– – 1.11% 19
2026
Q1 		$14.5M Buy
3,250,000
+1,750,000
+117% +$8.14M 1.1% 18
2025
Q4 		$8.25M Buy
+1,500,000
New +$7.28M 0.51% 28
2021
Q2 		– Sell
-820,440
Closed -$16.7M – 58
2021
Q1 		$16.7M Hold
820,440
– – 0.5% 35
2020
Q4 		$21.8M Hold
820,440
– – 0.65% 34
2020
Q3 		$18.4M Buy
+820,440
New +$19.3M 0.82% 28

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Casdin Capital's TSHA Position: Q2 2026 in Review

Casdin Capital held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 3,250,000 shares worth $22.1M. The position accounts for 1.11% of the portfolio, ranked #19.

Casdin Capital first reported a position in TSHA in Q3 2020 and has held it in 6 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Casdin Capital held 3,250,000 shares of Taysha Gene Therapies worth $22.1M as of Q2 2026.
  • Casdin Capital left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up 1.11% of Casdin Capital's portfolio in Q2 2026, its #19 holding.
  • Casdin Capital first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 6 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.